Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tucatinib DDI with Metformin in Healthy Subjects
NCT03826602Phase 1Completed
- Sponsor
- Seagen Inc.
- Start
- Feb 2019
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tucatinib in HER2-positive breast cancer, sponsored by Seagen Inc. Primary endpoints: Maximum observed plasma concentration of metformin up to 9 days, Time to maximum observed plasma concentration of metformin up to 9 days and 5 more. Started Feb 2019; status: completed.
02
Drugs
tucatinib
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT03826602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03826602.